PRDM16s transforms megakaryocyte-erythroid progenitors into myeloid leukemia–initiating cells

• Published in: Blood Vol. 134; no. 7; pp. 614 - 625
• Main Authors: Hu, Tianyuan, Morita, Kiyomi, Hill, Matthew C., Jiang, Yajian, Kitano, Ayumi, Saito, Yusuke, Wang, Feng, Mao, Xizeng, Hoegenauer, Kevin A., Morishita, Kazuhiro, Martin, James F., Futreal, P. Andrew, Takahashi, Koichi, Nakada, Daisuke
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 15.08.2019; American Society of Hematology
• Subjects: Animals; Cell Transformation, Neoplastic - genetics; Cell Transformation, Neoplastic - pathology; DNA-Binding Proteins - genetics; Gene Expression Regulation, Leukemic; Gene Regulatory Networks; Hematopoiesis and Stem Cells; Humans; Leukemia, Myeloid, Acute - genetics; Leukemia, Myeloid, Acute - pathology; Megakaryocyte-Erythroid Progenitor Cells - metabolism; Megakaryocyte-Erythroid Progenitor Cells - pathology; Mice, Inbred C57BL; Proto-Oncogene Proteins - genetics; Trans-Activators - genetics; Transcription Factors - genetics; Translocation, Genetic
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.2018888255

Oncogenic mutations confer on cells the ability to propagate indefinitely, but whether oncogenes alter the cell fate of these cells is unknown. Here, we show that the transcriptional regulator PRDM16s causes oncogenic fate conversion by transforming cells fated to form platelets and erythrocytes into myeloid leukemia stem cells (LSCs). Prdm16s expression in megakaryocyte-erythroid progenitors (MEPs), which normally lack the potential to generate granulomonocytic cells, caused AML by converting MEPs into LSCs. Prdm16s blocked megakaryocytic/erythroid potential by interacting with super enhancers and activating myeloid master regulators, including PU.1. A CRISPR dropout screen confirmed that PU.1 is required for Prdm16s-induced leukemia. Ablating PU.1 attenuated leukemogenesis and reinstated the megakaryocytic/erythroid potential of leukemic MEPs in mouse models and human AML with PRDM16 rearrangement. Thus, oncogenic PRDM16s expression gives MEPs an LSC fate by activating myeloid gene regulatory networks. •Prdm16s transforms MEP cells into myeloid leukemia stem cells.•Prdm16s activates PU.1 expression, which is required for Prdm16s-induced leukemia. [Display omitted]